TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $40.67.

A number of equities analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th.

TG Therapeutics Stock Down 5.1 %

TG Therapeutics stock opened at $37.35 on Friday. The firm has a market capitalization of $5.87 billion, a price-to-earnings ratio of -373.46 and a beta of 2.13. The firm has a 50 day simple moving average of $35.27 and a 200 day simple moving average of $30.85. TG Therapeutics has a 1-year low of $12.93 and a 1-year high of $43.32. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. On average, analysts predict that TG Therapeutics will post 0.08 earnings per share for the current year.

Insider Activity

In related news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Arizona State Retirement System raised its holdings in shares of TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company’s stock valued at $1,283,000 after buying an additional 364 shares in the last quarter. Blue Trust Inc. raised its stake in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 371 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of TG Therapeutics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company’s stock worth $440,000 after acquiring an additional 463 shares during the last quarter. Brookstone Capital Management boosted its stake in shares of TG Therapeutics by 3.7% in the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 624 shares in the last quarter. Finally, Daymark Wealth Partners LLC grew its holdings in shares of TG Therapeutics by 1.7% during the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company’s stock valued at $1,249,000 after purchasing an additional 689 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.